Comparison between Prothrombin Complex Concentrate (PCC) and Fresh Frozen Plasma (FFP) for the Urgent Reversal of Warfarin in Patients with Mechanical Heart Valves in a Tertiary Care Cardiac Center

Bahram Fariborz Farsad, Reza Golpira, Hamideh Najafi, Ziae Totonchi, Shirin Salajegheh, Hooman Bakhshandeh, Farshad Hashemian, Bahram Fariborz Farsad, Reza Golpira, Hamideh Najafi, Ziae Totonchi, Shirin Salajegheh, Hooman Bakhshandeh, Farshad Hashemian

Abstract

Fresh frozen plasma (FFP) and prothrombin complex concentrate (PCC) reverse oral anticoagulants such as Warfarin. We compared the standard dosage of FFP and PCC in terms of efficacy and safety for patients with mechanical heart valves undergoing interventional procedures while receiving Warfarin. Fifty patients were randomized (25 for each group) with mechanical heart valves [international normalized ratio (INR) >2.5]. FFP dosage was administered based on body weight (10-15 mL/Kg), while PCC dosage was administered based on both body weight and target INR. INR measurements were obtained at different time after PCC and FFP infusion. The mean ± SD of INR pre treatment was not significantly different between the PCC and FFP groups. However, over a 48-hour period following the administration of PCC and FFP, 76% of the patients in the PCC group and only 20% of the patients in the FFP group reached the INR target. Five (20%) patients in the PCC group received an additional dose of PCC, whereas 17 (68%) patients in the FFP group received a further dose of FFP (P=0.001). There was no significant difference between the two groups in Hb and Hct before and during a 48-hour period after PCC and FFP infusion. As regards safety monitoring and adverse drug reaction screening in the FFP group, the INR was high (INR > 2.5) in 86% of the patients. There was no report of hemorrhage in both groups. PCC reverses anticoagulation both effectively and safely while having the advantage of obviating the need to extra doses.

Keywords: Fresh frozen plasma; Prothrombin complex concentrates; Warfarin reversal.

Figures

Figure 1
Figure 1
INR fluctuations after PCC & FFP infusion

References

    1. Joseph B, Aziz H, Pandit V, Hays D, Kulvatunyou N, Yousuf Z, Tang A, O'Keeffe T, Green D, Friese RS, Rhee P. Prothrombin complex concentrate versus fresh-frozen plasma for reversal of coagulopathy of trauma: is there a difference? World J. Surg. 2014;38:1875–1881.
    1. Karaca MA, Erbil B, Ozmen MM. Use and effectiveness of prothrombin complex concentrates vs fresh frozen plasma in gastrointestinal hemorrhage due to warfarin usage in the ED. Am. J. Emerg. Med. 2014;32:660–664.
    1. Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet . 2009;374:565–576.
    1. Eitz T, shenk S, Fritzche D, Bairaktaris A, Wanger O, Koerfer R. International normalized ratio self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement. Ann. Thorac. Surg. 2008;85:949–955.
    1. Safaoui MN, Aazami R, Hotz H, Wilson MT, Margolies DR. A promising new alternative for the rapid reversal of warfarin coagulopathy in traumatic intracranial hemorrhage. Am. J. Surg. 2009;197:785–790.
    1. R. Demeyere S, Demeyere S, Gillardin J, Arnouty J, Strenger PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox. Sanguinis. 2010;99:251–260.
    1. Wallace Edvard L. Monitoring the nation’s blood supply. Transfusion . 2003;43:299–301.
    1. Kakkar N, Kaury R, Dhanoaz J. Improvement in fresh frozen plasma transfusion practice: results of an outcome audit. Transfus. Med. 2004;14:231–235.
    1. Contreras M, Ala FA, Greaves M, Jones J, Levin M, Machin SJ, Morgan C, Murphy W, Napier JA, Thomson AR. Guidelines for the use of fresh frozen plasma British committee for standards in haematology, working party of the blood transfusion task force. Transfus. Med. 1992;2:57–63.
    1. Stainsby D, Russel J, Cohen H, Lilleyman J. Reducing adverse events in blood transfusion. Br. J. Haematol. 2005;131:8–12.
    1. MacLennan S, Williamson LM. Risks of fresh frozen plasma and platelets. J. Trauma. 2006;60:46–50.
    1. Hanley JP. Warfarin reversal. J. Clin. Pathol. 2004;57:1132–1139.
    1. Ansell J, Hirsch J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and Management of the Vitamin K Antagonists American College of Chest Physicians evidencebased clinical practice guidelines 8th ed. . Chest . 2008;133:160–198.
    1. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med. J. Aust. 2004;181:492–497.
    1. Gohlke-Barwolf C, Kremer R. Prevention of thromboembolic events in valvular heart disease. Acta. Cardiol. 1996;51:129–142.
    1. Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. Lancet . 2007;370:439–448.
    1. Practice guidelines for perioperative blood transfusion and adjuvant therapies. An updated report by the American Society of Anesthesiologists task force on perioperative blood transfusion and adjuvant therapies. An updated report by the American Society of Anesthesiologists task force on perioperative blood transfusion and adjuvant therapies. Anesthesiol. 2006;105:198–208.
    1. The Society of thoracic surgeons blood conservation guideline task force, the Society of cardiovascular anesthesiologists special task force on blood transfusion. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of thoracic surgeons blood conservation guideline task force, the Society of cardiovascular anesthesiologists clinical practice guideline. Ann. Thorac. Surg. 2007;83:27–86.
    1. Despotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion . 2008;48:20–30.
    1. Levi M, Fries D, Gombotz H, van der Linden Ph, Nascimento B, Callum JL, Belisle S, Rizoli S, Hardy JF. Prevention and treatment of coagulopathy in patients receiving massive transfusions. Vox. Sanguinis. 2011;101:154–174.
    1. Guidelines for Reversal of Oral Anticoagulants including Warfarin and Phenindione. In: West Suffolk Hospital NHS Trust. Hospital Thrombosis Committee. 2011. [Cited 2011 April 7]. Available from: URL: .
    1. Butchart EG1, Gohlke-Bärwolf C, Antunes MJ, Tornos P, De Caterina R, Cormier B, Prendergast B, Iung B, Bjornstad H, Leport C, Hall RJ, Vahanian A. Recommendations for the management of patients after heart valve surgery. Europ. Heart J. 2005;26:2463–2471.
    1. Gilles Pernod, Anne Godiér, Claire Gozalo, Tremy B, Sie P. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding) Thrombosis Res. 2010;126:167–174.
    1. European Medicines Agency. In: Core SPC for human prothrombin complex products. West Suffolk Hospital NHS Trust. 2004. [Cited 2004 Nov 18]. Available from:URL: .
    1. Stuklis RG, O’Shaughnessy DF, Ohri SK. Novel approach to bleeding in patients undergoing cardiac surgery with liver dysfunction. Eur. J. Cardiothorac. Surg. 2001;19:219–220.
    1. Tanaka KA, Szlam F. Treatment of massive bleeding with prothrombin complex concentrate: argument for. J. Thromb. Haemost. 2010;8:2589–2591.
    1. Mendarte L, Munne M, Rodriguez S. Use of human prothrombin complex concentrate in patients with acquired deficiency and active or in high-risk severe bleeding. JCD. 2010
    1. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke . 1992;23:972–977.
    1. Ayako T, Tomoko S Kato, Kasuo K, Hideaki K, Masaki A, Kazuhico H, Kauo N, Toshiaki Noboru Oda. Prothrombin complex concentrate for rapid reversal of warfarin-induced anticoagulation and intracerebral hemorrhage in patients supported by a left ventricular assist device. Int. J. Gerontol. September . 2010;4:3.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere